GOSSAMER BIO, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $48.5M | $114.7M | $0 | $0 | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $37.6M | $36.1M | $38.5M | $47.6M | $45.8M | $49.7M | $39.1M |
| Operating Income | — | $-170.7M | $-59.9M | $-183.8M | $-218.6M | $-216.1M | $-234.0M | $-186.1M |
| Operating Margin | — | -352.2% | -52.2% | — | — | — | — | — |
| Interest Expense | — | — | — | $13.5M | $13.9M | $19.4M | $12.7M | $1.9M |
| Pretax Income | — | $-170.5M | $-55.6M | $-179.8M | $-229.4M | $-234.0M | $-243.4M | $-180.3M |
| Income Tax Expense | — | $-88.0K | $893.0K | $0 | $0 | — | — | $0 |
| Net Income | — | $-170.4M | $-56.5M | $-179.8M | $-229.4M | $-234.0M | $-243.4M | $-180.3M |
| Net Margin | — | -351.5% | -49.3% | — | — | — | — | — |
| EPS (Basic) | — | $-0.75 | $-0.25 | $-1.18 | $-2.71 | $-3.13 | $-3.55 | $-3.29 |
| EPS (Diluted) | — | $-0.75 | $-0.25 | $-1.18 | $-2.71 | $-3.13 | $-3.55 | $-3.29 |
| Shares Outstanding (Basic) | 234.7M | 228.5M | 226.2M | 152.6M | 84.6M | 74.8M | 68.5M | 54.7M |
| Shares Outstanding (Diluted) | 234.7M | 228.5M | 226.2M | 152.6M | 84.6M | 74.8M | 68.5M | 54.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |